'Remote pharmacy supervision could allow flexibility in a crisis'

The option to remotely supervise a pharmacy in a crisis as a last resort could be helpful for pharmacists in some situations, says contractor Mike Hewitson

Mike%20Hewitson%20resize.jpg

Whether pharmacies can ever be responsibly supervised without a pharmacist on-site has been a key debate in the sector over the last three years. The controversial issue arose again as a result of the pressures on the sector caused by the COVID-19 outbreak.

In March, the General Pharmaceutical Council (GPhC) announced that pharmacies could open in emergencies with a pharmacist accessible by video link or phone to enable them to continue supplying medicines. The council stressed that this should only happen when the responsible pharmacist has had to leave unavoidably at short notice and when no locum cover could be secured.

Pharmacy professionals are split on the topic. Mike Hewitson, owner of Beaminster Pharmacy in Dorset, says that, if carefully managed, the option of supervising remotely could help responsible pharmacists to continue to supply medicines in a crisis.

The decision to have a pharmacist supervise remotely could be used when "there is no other way my patients can access their medicines”, he tells C+D in a podcast.

“If it was snowing outside and not safe to get to work, and I have patients that need medicines, then potentially I probably would be prepared to [remotely supervise the pharmacy] short-term on a very occasional basis. But I certainly wouldn't be happy to do that to, for example, attend a meeting.”

He stresses that “it’s really important we keep pharmacists in pharmacies because it’s a really important part of the service we offer”. If a pharmacist does have to resort to supervising remotely, however, this should be “accountable, transparent and justified”, not a routine action or used as a cost-saving exercise, he says.

Listen to the podcast to hear more from Mr Hewitson on:

  • How the responsible pharmacist should be the one to make the decision on supervising remotely, not a superintendent pharmacist located outside the pharmacy.
  • The importance of having adequate safeguards for remote supervision.
  • The risks of replacing a pharmacist with an AI chat bot.
  • Every incident of remote supervision should be logged with the GPhC.

Chemist + Druggist pharmacy podcast · Contractor: Remote pharmacy supervision could allow flexibility in a crisis

Please note, the sound quality of this podcast may be affected as it has been recorded remotely during the COVID-19 outbreak.

Sign in or register for free

Latest from Analysis

Why I’ve launched a campaign against the RPS’s planned changes

 
• By 
 • comment

‘Vote no’ campaigner Martin Astbury tells C+D why he believes the RPS plans for change represent a shift away from pharmacist leadership and why members should vote against them this week…

CPE is negotiating in a very difficult and nuanced environment that few will have experienced

 
• By 
 • comment

I also read comments that CPE does not appreciate this critical position, and I fundamentally refute that. Knowing the colleagues, both elected and employed, at CPE as I do, this is far from the case.

It’s not just funding delays holding pharmacy back, it’s the old dinosaurs too...

 
• By 
 • comment

Community pharmacy is risk adverse, considered, and dare I say it, conservative. But, when it comes to the survival of pharmacy, we can’t afford to let the fear of change – or those resistant to it - hold us back.

More from Coronavirus

COVID-19 vaccination fees stagnate despite negotiator pleas

 
• By 
 • comment

Confirmation of the unchanging fees comes as NHS England (NHSE) has asked pharmacies to prepare for the autumn flu and COVID-19 vaccination programmes to start in October, or September for pregnant women.  

exclusive

Novavax COVID jab delivered by indie pharmacy in UK first

 
• By 
 • comment

The new private COVID-19 vaccine, manufactured by Novavax and delivered for the first time in the UK by an independent pharmacy, is almost half the price of the Pfizer jab offered by Boots.